IDDF2019-ABS-0257 Factors and models for predicting posthepatectomy liver failure in patients undergoing hepatic resection for hepatocellular carcinoma

Jonggi Choi, Danbi Lee, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung-Sang Lee, Kang Mo Kim
2019 Clinical Hepatology   unpublished
Methods Over 1548 RCTs on the use of UDCA as the treatment for NASH, from 2004 to 2018 have been reviewed. Estimation of the total subject populations in all these studies approximates almost 15,000 NASH patients. Outcome measures include both decreases in liver transaminases and improvement in histology. All the RCTs, even the current guidelines, offer different options, including the use of UDCA. Follow-up periods range from 4 weeks to 96 weeks. Results Of all the 1548 RCTs reviewed from
more » ... reviewed from 2004-2018, 15% showed no beneficial effects with the use of UDCA while 85% of RCTs showed decreasing transaminases and improvement in histology. Conclusions UDCA, through its Farsenoid Targeting mechanism, may yet become a frontline therapeutic option for NASH, thereby preventing its progression to cirrhosis and liver cancer.
doi:10.1136/gutjnl-2019-iddfabstracts.297 fatcat:bt4qyrbq3vak7b4wrpgrzvqr7e